Nursing and Pharmacy Time for Delivering Xeloda® Versus 5-Fluoruracil Regimens
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01801085|
Recruitment Status : Terminated (Slow recruitment pace)
First Posted : February 28, 2013
Last Update Posted : February 2, 2017
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||21 participants|
|Official Title:||The Impact of Nursing and Pharmacy Care Between Xeloda® and 5-Fluoruracil Regimens in the Management of Colorectal Cancer (CRC) in Hong Kong|
|Study Start Date :||October 2011|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||December 2014|
Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and 2 5-FU 400 mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d 1 and d2 Oxaliplatin (Eloxatin) 85 mg/m2 iv d1 Q2w x 12 cycles
Capecitabine (Xeloda) 1000 mg/m2 po bid x 14 days Oxaliplatin (Eloxatin) 130 mg/m2 iv over 2 hrs d1 Q3w x 8 cycles
- Composite preparation, dispensing and administration time [ Time Frame: Up to 6 months after the initiation of chemotherapy ]Composite time is measured via real-time recording. Total length of the said time points are to be recorded using a stop-watch and the sum is tabulated in the end.
- Capital item utilization (hospital bed and infusion pump) [ Time Frame: Up to 6 months after the initiation of chemotherapy ]Capital item utilization is measured as the amount of time each healthcare resource is used and the associated cost for usage.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01801085
|Princess Margaret Hospital|
|Kowloon, Hong Kong|
|Queen Elizabeth Hospital|
|Kowloon, Hong Kong|
|Principal Investigator:||Vivian WY Lee, PharmD||CUHK|